Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclic alternating patterns of encephalopathy: implications for triphasic waves in noncomatose patients with metabolic-toxic encephalopathies.

Critical care (London, England)·2026
Same author

Centroparietal periodic sharp-wave discharges and biphasic complexes: Novel EEG biomarkers for early diagnosis of Rasmussen encephalitis.

Epilepsy & behavior reports·2026
Same author

Intracranial and Peripheral Inflammatory Biomarkers Predict Futile Recanalization After Endovascular Treatment.

Stroke·2026
Same author

Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.

Epilepsia·2026
Same author

Automated MRI-based atrophy patterns to improve the diagnosis of generalized epilepsies in outpatient care.

Seizure·2026
Same author

Hypoperfusion on Early MRI Despite Successful Thrombectomy: A Prospective Imaging and Inflammatory Biomarkers Study.

Stroke·2026
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Dramatic weight loss with rufinamide.

Isabelle Mourand1, Arielle Crespel, Philippe Gelisse

  • 1Department of Neurology, Gui de Chauliac Hospital, Montpellier, France. i-mourand@chu-montpellier.fr

Epilepsia
|July 12, 2012
PubMed
Summary
This summary is machine-generated.

Rufinamide (RUF) can cause significant weight loss in adult epilepsy patients, contrary to its "weight-neutral" classification. This adverse effect, potentially linked to appetite loss, may impact underweight individuals, necessitating further study on dose adjustments.

More Related Videos

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Related Experiment Videos

Last Updated: May 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Medicine

Background:

  • Rufinamide (RUF) is an antiepileptic drug used for Lennox-Gastaut syndrome.
  • Adverse events typically include drowsiness and irritability.
  • RUF is generally considered weight-neutral.

Purpose of the Study:

  • To investigate the incidence of weight loss in adult patients treated with Rufinamide.
  • To assess the clinical significance and potential contributing factors of RUF-induced weight loss.

Main Methods:

  • Observational study of 15 adult patients receiving RUF as add-on therapy.
  • Dosage ranged from 800-2,400 mg/day (23.5-57.1 mg/kg/day).
  • Weight and BMI changes were monitored; patient-reported appetite and nausea were recorded.

Main Results:

  • 47% of patients experienced clinically significant weight loss (7/15).
  • Body Mass Index (BMI) decreased by 7.3-18.7%.
  • Weight loss occurred in patients with normal and underweight BMI, with 71% of affected patients being underweight prior to treatment.

Conclusions:

  • Rufinamide can cause significant weight loss in adult patients, challenging its weight-neutral status.
  • Weight loss may be associated with reduced appetite and nausea.
  • Lower starting doses and slower titration might mitigate this adverse effect, requiring further investigation.